CurrentCignaPolicy IP0049

Antiseizure Medications - Vigabatrin

Cigna coverage policy governing prior authorization, approved indications, and product-specific requirements for vigabatrin formulations for members covered under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyAntiseizure Medications - Vigabatrin

Policy CodePolicy IP0049

Change TypeRevised (authorization durations) and Added (formulation)

Effective Date

Next Review Date

Key ActionObtain prior authorization; initial approvals require specialist prescription/consultation and are time-limited per indication.

SourceLink

POLICY UPDATE CHANGES

Updated coverage policy title from Vigabatrin to Antiseizure Medications - Vigabatrin and modified authorization durations for infantile spasms and treatment-refractory complex partial seizures.

Vigafyde formulation was added to the policy and Vigadrone oral solution was removed from the preferred product table.

2FDA-approved indication groups

6 moInfantile spasms approval

3 moInitial refractory CP seizures

REMSREMS required

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Vigabatrin

FDA-Approved Indications

Covered when ALL of the following are met for each FDA‑approved indication:

Infantile Spasms - Approve for 6 months: Patient is ≤ 2 years of age; AND vigabatrin is being used as monotherapy; AND the medication is prescribed by or in consultation with a neurologist; AND preferred product criteria are met for the product(s)6 months

Per policy, use lowest dosage/shortest exposure; withdraw if no substantial benefit within 2–4 weeks.

Treatment‑Refractory Complex Partial Seizures - Approve

Initial Therapy - Approve for 3 months: Patient is ≥ 2 years of age; AND patient has tried and/or is concomitantly receiving at least three other antiseizure medications; AND the medication is prescribed by or in consultation with a neurologist; AND preferred product criteria are met for the product(s)3 months
Currently Receiving Vigabatrin - Approve for 1 year: Patient is currently receiving vigabatrin and is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber1 year

Preferred Product / Formulation Exceptions

Product-specific preferred product criteria (formulation exceptions):

Employer Plans - Brand exceptions: Approval of Sabril, Vigadrone, or Vigafyde requires that the patient has tried the bioequivalent generic product AND cannot take the generic because, per the prescriber, a formulation difference in inactive ingredient(s) (for example dyes, fillers, preservatives) would result in a significant allergy or serious adverse reaction.

Applies to Employer Plans; examples of inactive ingredient differences include dyes, fillers, preservatives.

Individual and Family Plans - Brand exceptions: Approval of Sabril or Vigafyde requires that the patient has tried the bioequivalent generic product AND cannot take the generic because, per the prescriber, a formulation difference in inactive ingredient(s) (for example dyes, fillers, preservatives) would result in a significant allergy or serious adverse reaction. Receipt of sample product does not satisfy criteria.

Applies to Individual and Family Plans.

Vigabatrin for any use other than the FDA‑approved indications specified in this policy is considered not medically necessary and is not eligible for coverage under Cigna‑administered health benefit plans. Criteria will be updated as new published data become available.

Use of vigabatrin for indications other than infantile spasms or treatment‑refractory complex partial seizures is considered not medically necessary and will be denied. Coverage criteria will be revised if new evidence emerges.

Coding and Monitoring

Covered/Applicable Codesmixed

No codes listed

Vision monitoring frequency

Baseline assessmentVision assessment at baseline (no later than 4 weeks after starting vigabatrin)

On-therapy monitoringVision assessment at least every 3 months during therapy

Post-discontinuation follow-upVision assessment about 3–6 months after discontinuation of therapy

Provider Actions, Prior Authorization, and Denials

Prior Authorization

Prior Authorization Required

Prior authorization is required for benefit coverage of all vigabatrin products. Initial approval requires prescription by or consultation with a specialist (neurologist). All approvals are provided for the duration noted in the policy; when duration is expressed in months, 1 month = 30 days.

Prior authorization required for all vigabatrin products.
Initial prescription must be by or in consultation with a specialist (neurologist).
Approval durations follow policy-specified lengths; 1 month = 30 days.

Step Therapy

Step/Conservative Therapy Requirement

For treatment-refractory complex partial seizures, initial approval requires evidence that the patient has tried and/or is concomitantly receiving at least three other antiseizure medications (examples include valproic acid, gabapentin, phenytoin, carbamazepine, oxcarbazepine, lacosamide, levetiracetam, zonisamide, perampanel (Fycompa), lamotrigine, topiramate, rufinamide, tiagabine, felbamate, stiripentol (Diacomit), and clobazam).

Background

Vigabatrin is an antiseizure medication indicated specifically as monotherapy for infantile spasms in patients approximately 1 month to 2 years of age and as adjunctive therapy for certain patients with treatment‑refractory complex partial seizures (typically patients ≥2 years who have not responded to multiple alternatives). Use is limited by a boxed warning for permanent vision loss; because of this risk the drug is managed through a restricted access/monitoring program and clinicians should use the lowest effective dose for the shortest duration necessary. Visual function must be assessed at baseline and periodically during and after treatment, and therapy should be discontinued if a patient does not demonstrate substantial clinical benefit within the timeframe specified for the indication.

Definitions and Program Requirements

Substantial clinical benefit — definition

DefinitionA clinically meaningful reduction in seizure frequency, severity and/or duration as determined by the prescriber

Infantile spasms withdrawal timeframeIf substantial benefit is not observed within 2–4 weeks, vigabatrin should be withdrawn

Refractory complex partial seizures withdrawal timeframeIf substantial benefit is not observed within 3 months, vigabatrin should be withdrawn

Vigabatrin REMS Program — summary

Program requirementVigabatrin is available only through a restricted access program (Vigabatrin REMS Program) because of a boxed warning for permanent vision loss

Monitoring mandated by REMSVision must be assessed at baseline, periodically during treatment, and after treatment per REMS and product labeling

Policy Summary

PayerCigna

PolicyAntiseizure Medications - Vigabatrin

Policy CodePolicy IP0049

Change TypeRevised (authorization durations) and Added (formulation)

Effective Date

Next Review Date

Key ActionObtain prior authorization; initial approvals require specialist prescription/consultation and are time-limited per indication.

SourceLink

On This Page

Initial therapy for treatment-refractory complex partial seizures: documentation of ≥ 3 prior or concomitant antiseizure medications required.

Examples of antiseizure medications: valproic acid; gabapentin; phenytoin; carbamazepine; oxcarbazepine; lacosamide; levetiracetam; zonisamide; perampanel (Fycompa); lamotrigine; topiramate; rufinamide; tiagabine; felbamate; stiripentol (Diacomit); clobazam.

Documentation Required

Prescriber and Approval Duration Requirements

Vigabatrin must be prescribed by or in consultation with a specialist (neurologist). Approvals are provided for specified durations depending on indication: infantile spasms — approve for 6 months when criteria met; treatment-refractory complex partial seizures — initial therapy approve for 3 months when criteria met, continuation for patients currently receiving vigabatrin approve for 1 year if responding to therapy.

Prescriber requirement: neurologist or in consultation with a neurologist.
Infantile spasms: approval duration = 6 months when ALL criteria are met (patient ≤ 2 years, monotherapy, specialist prescribing/consultation, preferred product criteria).
Treatment-refractory complex partial seizures - Initial therapy: approval duration = 3 months when ALL criteria are met (patient ≥ 2 years, ≥ 3 antiseizure meds tried/concomitant, specialist prescribing/consultation, preferred product criteria).
Treatment-refractory complex partial seizures - Ongoing therapy: approval duration = 1 year if patient is responding to therapy.

Denial Risk

Denial Triggers

Claims submitted without a covered diagnosis or procedure code or not meeting the policy criteria will be denied. Prior authorization is required; lack of prior authorization or failure to meet the criteria (including prescriber specialty, step-therapy requirements, or required documentation of prior/concomitant antiseizure medications) are denial triggers.

Claims lacking covered diagnosis/procedure codes will be denied as not covered.
Failure to obtain prior authorization will result in denial.
Not meeting policy criteria (e.g., prescriber specialty, step therapy, approval-duration conditions, or required documentation) are grounds for denial.

Risk justificationREMS is required due to unpredictable, potentially irreversible vision loss that can occur within weeks or after long‑term exposure